Product Code: GVR-4-68040-633-5
Surgical Gowns Level AAMI 3 Market Summary
The global surgical gowns level AAMI 3 market size was estimated at USD 756.52 million in 2024 and is projected to reach USD 1,985.77 million by 2033, growing at a CAGR of 11.27% from 2025 to 2033. This growth is attributed to the rising surgical procedure volumes, the increasing prevalence of healthcare-associated infections, and stringent global infection prevention and control standards.
The aging global population further supports the market expansion, the growing demand for moderate barrier protection gowns in inpatient and outpatient settings, and heightened awareness of surgical safety, particularly post-pandemic. In addition, innovation in gown materials and healthcare infrastructure improvements in emerging economies are anticipated to boost market adoption further over the forecast period. According to a study by the CDC, approximately 1 in every 31 hospitalized patients in the U.S. acquires a healthcare-associated infection, translating to an estimated 633,300 cases annually. In 2023, the Pennsylvania Patient Safety Reporting System recorded 23,970 HAI incidents reported by long-term care facilities across the state, highlighting the ongoing challenge of infection control in acute and extended care settings.
The rising incidence of healthcare-associated infections, including Surgical Site Infections (SSIs), Methicillin-Resistant Staphylococcus aureus (MRSA), Clostridium difficile infections, and Central Line-Associated Bloodstream Infections (CLABSIs), is a significant factor fueling the demand for AAMI Level 3 surgical gowns. These infections compromise patient safety, leading to longer hospital stays, increased morbidity, and higher healthcare costs. Among these, CLABSIs are particularly concerning in surgical and intensive care settings, where patients require invasive devices like central venous catheters. Proper use of personal protective equipment, including surgical gowns with moderate barrier protection, is critical in reducing contamination risk during line insertions and surgical procedures. In response to these risks, healthcare institutions are adopting more stringent infection prevention and control protocols supported by CDC, WHO, and ECDC recommendations. AAMI Level 3 gowns, known for their balance of comfort and fluid resistance, are increasingly used in settings with moderate exposure to blood and bodily fluids, including operating rooms and intensive care units. The global focus on reducing HAIs, especially in light of rising antimicrobial resistance, continues to drive strong demand for high-standard protective apparel, boosting the market. According to the Australian Institute of Health and Welfare, 2023-2024, 1,699 SABSI cases were reported across public hospitals, occurring over 22.7 million patient care days, equating to a national rate of 0.75 cases per 10,000 patient days.
The data below highlights the top 15 U.S. states most affected by Central Line-Associated Bloodstream Infections (CLABSIs) in 2022. These high-capacity healthcare hubs perform a significant volume of invasive procedures involving central lines, increasing the risk of bloodstream infections. As a result, hospitals in these states are under greater pressure to implement rigorous infection prevention protocols, including the mandatory use of AAMI Level 3 surgical gowns that offer essential fluid and microbial barrier protection during central line insertions and maintenance.
Global Surgical Gowns Level AAMI 3 Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global surgical gowns level AAMI 3 market report on the basis of gown type, surgery, end use, usability, and region:
- Gown Type Outlook (Revenue, USD Million; Volume Unit, Price USD; 2021 - 2033)
- Fabric Reinforced
- Non-fabric Reinforced
- Surgery Outlook (Revenue, USD Million; Volume Unit, Price USD; 2021 - 2033)
- General Surgery
- Orthopedic Surgery
- Endoscopic Surgery
- Gynecological Surgery
- Mastectomy
- Others
- Usability Outlook (Revenue, USD Million; Volume Unit, Price USD; 2021 - 2033)
- Disposable Gowns
- Reusable Gowns
- End Use Outlook (Revenue, USD Million; Volume Unit, Price USD; 2021 - 2033)
- Operating Room
- Emergency Room
- Intensive Care Unit (ICU)
- Others
- Regional Outlook (Revenue, USD Million; Volume Unit, Price USD; 2021 - 2033)
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Gown Type
- 1.1.2. Surgery
- 1.1.3. Usability
- 1.1.4. End Use
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Surgical Gowns Level AAMI 3 Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing number of surgical procedures
- 3.2.1.2. Rising burden of healthcare associated infections
- 3.2.1.3. Introduction of innovative and advanced surgical gowns
- 3.2.1.4. Rising hospitalization
- 3.2.2. Market restraint analysis
- 3.2.2.1. Recalls of surgical gowns
- 3.2.3. Market opportunity analysis
- 3.2.3.1. Growing demand for reusable surgical gowns
- 3.2.3.2. Improvements in public and private healthcare infrastructure
- 3.2.3.3. Growth potential in emerging economies in the surgical gowns market
- 3.2.3.4. Development of antimicrobial surgical gowns
- 3.2.4. Market challenge analysis
- 3.2.4.1. Potential complications and risks associated with surgical gowns
- 3.3. Surgical Gowns Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
Chapter 4. Surgical Gowns Level AAMI 3 Market: Gown Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Surgical Gowns Level AAMI 3 Market Gown Type Movement Analysis
- 4.3. Global Surgical Gowns Level AAMI 3 Market Size & Trend Analysis, by Gown Type, 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 4.4. Fabric Reinforced
- 4.4.1. Fabric reinforced market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 4.5. Non-fabric Reinforced
- 4.5.1. Non-fabric reinforced market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
Chapter 5. Surgical Gowns Level AAMI 3 Market: Surgery Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Surgical Gowns Level AAMI 3 Market Surgery Movement Analysis
- 5.3. Global Surgical Gowns Level AAMI 3 Market Size & Trend Analysis, by Surgery, 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.4. Orthopedic Surgery
- 5.4.1. Orthopedic surgery market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.5. General Surgery
- 5.5.1. General surgery market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.6. Gynecological Surgery
- 5.6.1. Gynecological surgery market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.7. Endoscopic Surgery
- 5.7.1. Endoscopic surgery market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.8. Mastectomy
- 5.8.1. Mastectomy market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 5.9. Others
- 5.9.1. Other market estimates and forecasts 2021 to 2033 (USD Million, Volume Unit, Price USD)
Chapter 6. Surgical Gowns Level AAMI 3 Market: Usability Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Surgical Gowns Level AAMI 3 Market Usability Movement Analysis
- 6.3. Global Surgical Gowns Level AAMI 3 Market Size & Trend Analysis, by Usability, 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 6.4. Disposable Gowns
- 6.4.1. Disposable gowns market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 6.5. Reusable Gowns
- 6.5.1. Reusable gowns market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
Chapter 7. Surgical Gowns Level AAMI 3 Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Surgical Gowns Level AAMI 3 Market End Use Movement Analysis
- 7.3. Global Surgical Gowns Level AAMI 3 Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 7.4. Operating Room
- 7.4.1. Operating room market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 7.5. Emergency Room
- 7.5.1. Emergency room market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 7.6. Intensive Care Unit (ICU)
- 7.6.1. Intensive Care Unit (ICU) market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
- 7.7. Others
- 7.7.1. Other market estimates and forecast 2021 to 2033 (USD Million, Volume Unit, Price USD)
Chapter 8. Surgical Gowns Level AAMI 3 Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 8.3. North America
- 8.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million, Volume Unit, Price USD)
- 8.3.2. U.S.
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Competitive scenario
- 8.3.2.3. Regulatory framework
- 8.3.2.4. Reimbursement scenario
- 8.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
- 8.3.3. Canada
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Competitive scenario
- 8.3.3.3. Regulatory framework
- 8.3.3.4. Reimbursement scenario
- 8.3.3.5. Canada market estimates and forecasts, 2021 - 2033
- 8.3.4. Mexico
- 8.3.4.1. Key country dynamics
- 8.3.4.2. Competitive scenario
- 8.3.4.3. Regulatory framework
- 8.3.4.4. Reimbursement scenario
- 8.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Competitive scenario
- 8.4.1.3. Regulatory framework
- 8.4.1.4. Reimbursement scenario
- 8.4.1.5. UK market estimates and forecasts, 2021 - 2033
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory framework
- 8.4.2.4. Reimbursement scenario
- 8.4.2.5. Germany market estimates and forecasts, 2021 - 2033
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory framework
- 8.4.3.4. Reimbursement scenario
- 8.4.3.5. France market estimates and forecasts, 2021 - 2033
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Competitive scenario
- 8.4.4.3. Regulatory framework
- 8.4.4.4. Reimbursement scenario
- 8.4.4.5. Italy market estimates and forecasts, 2021 - 2033
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Competitive scenario
- 8.4.5.3. Regulatory framework
- 8.4.5.4. Reimbursement scenario
- 8.4.5.5. Spain market estimates and forecasts, 2021 - 2033
- 8.4.6. Denmark
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Competitive scenario
- 8.4.6.3. Regulatory framework
- 8.4.6.4. Reimbursement scenario
- 8.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Competitive scenario
- 8.4.7.3. Regulatory framework
- 8.4.7.4. Reimbursement scenario
- 8.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
- 8.4.8. Norway
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Competitive scenario
- 8.4.8.3. Regulatory framework
- 8.4.8.4. Reimbursement scenario
- 8.4.8.5. Norway market estimates and forecasts, 2021 - 2033
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Competitive scenario
- 8.5.1.3. Regulatory framework
- 8.5.1.4. Reimbursement scenario
- 8.5.1.5. Japan market estimates and forecasts, 2021 - 2033
- 8.5.2. India
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory framework
- 8.5.2.4. Reimbursement scenario
- 8.5.2.5. India market estimates and forecasts, 2021 - 2033
- 8.5.3. China
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory framework
- 8.5.3.4. Reimbursement scenario
- 8.5.3.5. China market estimates and forecasts, 2021 - 2033
- 8.5.4. South Korea
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory framework
- 8.5.4.4. Reimbursement scenario
- 8.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
- 8.5.5. Australia
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory framework
- 8.5.5.4. Reimbursement scenario
- 8.5.5.5. Australia market estimates and forecasts, 2021 - 2033
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Competitive scenario
- 8.5.6.3. Regulatory framework
- 8.5.6.4. Reimbursement scenario
- 8.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Competitive scenario
- 8.6.1.3. Regulatory framework
- 8.6.1.4. Reimbursement scenario
- 8.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Competitive scenario
- 8.6.2.3. Regulatory framework
- 8.6.2.4. Reimbursement scenario
- 8.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Competitive scenario
- 8.7.1.3. Regulatory framework
- 8.7.1.4. Reimbursement scenario
- 8.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Competitive scenario
- 8.7.2.3. Regulatory framework
- 8.7.2.4. Reimbursement scenario
- 8.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Competitive scenario
- 8.7.3.3. Regulatory framework
- 8.7.3.4. Reimbursement scenario
- 8.7.3.5. UAE market estimates and forecasts, 2021 - 2033
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Competitive scenario
- 8.7.4.3. Regulatory framework
- 8.7.4.4. Reimbursement scenario
- 8.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Global Key company market share analysis, 2024
- 9.3.4. Cardinal Health
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Product benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. Medline Industries, LP
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. Molnlycke Health Care AB
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Product benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Medicom
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Product benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. Encompass Group, LLC.
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Product benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. Taromed
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Product benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. Cortex Products Solution Pvt. Ltd
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Product benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. Nippon Encon Manufacturing Co., Ltd.
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Product benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.12. Owens & Minor
- 9.3.12.1. Company overview
- 9.3.12.2. Financial performance
- 9.3.12.3. Product benchmarking
- 9.3.12.4. Strategic initiatives
- 9.3.13. Medilivescare Manufacturing Pvt. Ltd.
- 9.3.13.1. Company overview
- 9.3.13.2. Financial performance
- 9.3.13.3. Product benchmarking
- 9.3.13.4. Strategic initiatives
- 9.3.14. Boston Scientific Corporation
- 9.3.14.1. Company overview
- 9.3.14.2. Financial performance
- 9.3.14.3. Product benchmarking
- 9.3.14.4. Strategic initiatives
- 9.3.15. Henry Schein, Inc.
- 9.3.15.1. Company overview
- 9.3.15.2. Financial performance
- 9.3.15.3. Product benchmarking
- 9.3.15.4. Strategic initiatives
- 9.3.16. Standard Textile Co., Inc.
- 9.3.16.1. Company overview
- 9.3.16.2. Financial performance
- 9.3.16.3. Product benchmarking
- 9.3.16.4. Strategic initiatives
- 9.3.17. Dynarex Corporation
- 9.3.17.1. Company overview
- 9.3.17.2. Financial performance
- 9.3.17.3. Product benchmarking
- 9.3.17.4. Strategic initiatives
- 9.3.18. Rankinc
- 9.3.18.1. Company overview
- 9.3.18.2. Financial performance
- 9.3.18.3. Product benchmarking
- 9.3.18.4. Strategic initiatives
- 9.3.19. LDI Solutions, LLC
- 9.3.19.1. Company overview
- 9.3.19.2. Financial performance
- 9.3.19.3. Product benchmarking
- 9.3.19.4. Strategic initiatives
- 9.3.20. Vannin Healthcare
- 9.3.20.1. Company overview
- 9.3.20.2. Financial performance
- 9.3.20.3. Product benchmarking
- 9.3.20.4. Strategic initiatives
- 9.3.21. RUHOF
- 9.3.21.1. Company overview
- 9.3.21.2. Financial performance
- 9.3.21.3. Product benchmarking
- 9.3.21.4. Strategic initiatives
- 9.4. Heat Map Analysis/ Company Market Position Analysis
- 9.5. Estimated Company Market Share Analysis, 2024
- 9.6. List of Other Key Market Players